Emerald Advisers LLC Has $28.87 Million Stake in LivaNova PLC $LIVN

Emerald Advisers LLC raised its stake in LivaNova PLC (NASDAQ:LIVN) by 2.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 551,162 shares of the company’s stock after purchasing an additional 12,163 shares during the quarter. Emerald Advisers LLC owned 1.01% of LivaNova worth $28,870,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of the stock. Invesco Ltd. boosted its holdings in LivaNova by 714.7% during the 2nd quarter. Invesco Ltd. now owns 1,028,713 shares of the company’s stock worth $46,313,000 after acquiring an additional 902,447 shares during the last quarter. Scopia Capital Management LP purchased a new stake in shares of LivaNova in the second quarter valued at about $36,657,000. Artisan Partners Limited Partnership lifted its position in shares of LivaNova by 112.9% during the second quarter. Artisan Partners Limited Partnership now owns 1,247,609 shares of the company’s stock valued at $56,167,000 after purchasing an additional 661,480 shares in the last quarter. AQR Capital Management LLC boosted its holdings in LivaNova by 30.5% during the second quarter. AQR Capital Management LLC now owns 2,049,820 shares of the company’s stock worth $92,201,000 after purchasing an additional 478,525 shares during the last quarter. Finally, M&G PLC bought a new stake in LivaNova in the 2nd quarter worth about $11,762,000. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on LIVN. Robert W. Baird set a $75.00 target price on shares of LivaNova in a research report on Tuesday, December 16th. Stifel Nicolaus increased their price target on LivaNova from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d+)” rating on shares of LivaNova in a report on Monday, December 29th. The Goldman Sachs Group restated a “neutral” rating and issued a $66.00 price objective on shares of LivaNova in a research note on Friday, January 9th. Finally, KeyCorp started coverage on LivaNova in a research note on Friday, December 19th. They set an “overweight” rating and a $81.00 target price on the stock. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $69.38.

LivaNova Stock Up 0.6%

Shares of NASDAQ LIVN opened at $63.27 on Thursday. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The stock has a market capitalization of $3.46 billion, a PE ratio of -15.82 and a beta of 0.97. LivaNova PLC has a one year low of $32.48 and a one year high of $65.57. The business’s fifty day moving average price is $61.71 and its 200-day moving average price is $55.00.

About LivaNova

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.